Here you will find EURenOmics specific news.
For news directly from the European Commission, please use the links to the left.
Registration is open for the 3rd IRDiRC Conference in Paris, France
We invite you to join us at the 3rd conference of the International Rare Diseases Research Consortium (IRDiRC), which will take place February 8-9, 2017 in Paris, France at the conference center of Université Pierre et Marie Curie (UPMC) Jussieu.
A strong and exciting program has been put together, with 3 plenary sessions and 4 parallel sessions, featuring prominent international speakers. At a glance, the program will start by discussing the state of rare diseases research on a global scale, and will be followed by highlights of transformative efforts within the areas of foundational, diagnostics and therapeutics research. On the second day, new approaches to rare diseases research and trends in the field will be highlighted. The conference will close by discussing how to transform rare diseases research over the course of the next 10 years, including a panel discussion on the next set of IRDiRC goals for 2017-2027.
In addition to compelling talks, the 3rd IRDiRC Conference offers an array of networking opportunities for a diverse set of rare disease professionals and stakeholders from the rare disease world. Young investigators are encouraged to submit abstracts for oral and poster presentations.
Registration and abstract submission is now open, and the early registration rate is in effect until November 30, 2016. Reduced rates are available for trainees, patient advocates, and IRDiRC Scientific Committee and Task Force members.
For more information and registration, go to www.irdirc-conference.org.
The second EURenOmics Newsletter has been published
EURenOmics has just published its second newsletter. It can be downloaded here or via the right sidebar.
The next version is planned for the fall 2016 and we expect around two newsletters per year. Check back here for more information.
Third Periodic Report approved by the EC
The European Commission has approved the third Periodic Report from EURenOmics without any major comments. EURenOmics has been very successful during its third reporting period, ranging from 01. October 2014 to 31. September 2015.
In the first three years of its existence, the Consortium has exhibited impressive scientific dissemination activities. More than 5 publications per month were published in the second and third project year. To date, 152 publications acknowledging EURenOmics funding appeared in scientific journals, thereof 1 in the New England Journal of Medicine, 4 in The Lancet, 3 in Nature Genetics, 1 in Nature Medicine, 3 in the Journal of Clinical Investigation, and 35 in the top nephrology journals JASN and Kidney International. A cumulative impact factor of 1212 (mean 8.0 per publication) was achieved. The fraction of publications coauthored by several EURenOmics partners increased from 17.7% in 2014 to 30.8% in 2015, demonstrating the growing collaboration among the Consortium’s partners.
In addition to the excellent publication record, the partners disseminated their research findings at numerous scientific and health research meetings. Since the start of the project, 393 oral presentations were given (373 at scientific meetings and 20 to a wider public) and 62 posters were shown; 317 talks/posters were presented at international, and 138 at national meetings.
A summary of the third project year of EURenOmics can be found following the link below:
EURenOmics Project Summary Year 3
EURenOmics is part of the International Digital Nephropathology Network (INTEGRATE), supported by Leica Biosystems
The INTERNATIONAL DIGITAL NEPHROPATHOLOGY NETWORK (INTEGRATE) is a world wide collaborative effort of three consortia: NEPTUNE, EURenOmics and China-DiKip, focused on the standardization of the renal biopsy profile. In an effort to fight renal diseases, the INTEGRATE alliance of distinguished thought leaders in nephrology and pathology came together to discuss the standardization of pathology scoring processes for globalization of the renal biopsy assessment. The first symposia were held in San Diego, CA, early November, in conjunction with the American Society of Nephrology conference.
We are happy to announce that this collaborative effort is supported by Leica Biosystems. For more info, see the Leica Biosystems press release.
The first EURenOmics Newsletter has been published
EURenOmics has just published its first newsletter. It can be downloaded here or via the right sidebar.
The next version is planned for September 2015 and new editions should come out roughly two or three times a year. Check back here for more information.
Second Periodic Report approved by the EC
The European Commission has approved the second Periodic Report from EURenOmics without any major comments. EURenOmics has been very successful during its second reporting period, ranging from 01. October 2013 to 31. September 2014.
In the first two years of its existence, the Consortium has exhibited impressive scientific dissemination activities. The consortium partners published 92 publications in scientific journals, with a cumulative impact factor of 769 (mean 8.7 per publication). In addition, the partners disseminated their research findings at numerous scientific and health research meetings. Since the start of the project, 249 oral presentations were given (241 at scientific meetings and 8 to a wider public) and 35 posters were shown; 154 presentations were made at international, and 95 at national meetings.
A summary of the second project year of EURenOmics can be found following the link below:
EURenOmics Project Summary Year 2
Grant Agreement signed
EURenOmics unites 19 academic and 8 SME partners from 10 European countries and the US in an international consortium of scientific excellence, bringing together leading clinical, genetic and translational researcher in an unprecedented clinical research network in the field of rare kidney disease.
As the highest ranking proposal of its call, the project was awarded 12 million Euros to study the underlying causes and molecular pathways of several rare and neglected kidney disorders with eminent need and potential for diagnostic and therapeutic progress, using latest “Omics” technologies. Besides the elucidation of fundamental scientific questions, the project will focus strongly on the development of innovative diagnostic tools and biomarkers as well as models for the screening of potential therapeutic agents. This could open the possibility of individualized therapies for the benefit of the more than 30,000 newly diagnosed patients per year suffering from these debilitating kidney diseases.